Parand Darou Pharma Parand Darou Pharma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Levena Biopharma.

    Client Virtual Booth

    LEVENA BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Levena Biopharma
    China Flag
    Country
    Country
    China
    Address
    Address
    B8-301, Xinghu Street SIP, Suzhou, 215123 China
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.levenabiopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/levena-biopharma-co-ltd/about/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Shanghai Escugen Biotechnology Co., Ltd., a Partner of Levena Biopharma, a Sorrento Company, Releases Positive Results From a First-in-Human Study of ES...

    Details:

    ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8.


    Lead Product(s): TROP2 Antibody-drug Conjugate

    Therapeutic Area: Oncology Product Name: ESG401

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Recipient: Shanghai Escugen Biotechnology

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-H...

    Details:

    A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.


    Lead Product(s): A166

    Therapeutic Area: Oncology Product Name: A166

    Highest Development Status: Phase IIProduct Type: Large molecule

    Recipient: Sichuan Kelun Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In...

    Details:

    A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.


    Lead Product(s): A166

    Therapeutic Area: Oncology Product Name: A166

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Sichuan Kelun Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Navrogen and Levena collaborate to Develop Antibody Drug Conjugates

    Details:

    ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies.


    Lead Product(s): Antibody drug conjugates

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Navrogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 04, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-usa-llc-m-2024-07-08

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search